Portola Pharmaceuticals — Corporate Update (January 2019)
21 slides from Portola Pharmaceuticals's corporate update, Jan 8, 2019
Slide 1: Charting Our Course
Charting Our Course Tuesday, January 8, 2019 Scott Garland President & CEO Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases you can identify these statements by forward-looking words, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate
Slide 3: Gaspar De Portola
Gaspar De Portola For investor discussions only. Not for promotional use.
Slide 4: Progress on our Journey to Success
For investor discussions only. Not for promotional use. Progress on our Journey to Success OCT NOV DEC JAN FEB MAR
Slide 5: Portola Today
Portola Today Mardi Dier Chief Financial Officer & Chief Business Officer John Curnutte, M.D., Ph.D. Research & Development Scott Garland President & CEO Glenn Brame Technical Operations John Moriarty General Counsel & Secretary Ernie Meyer Chief Human Resources Officer
Slide 6: ANDEXXA
ANDEXXA For investor discussions only. Not for promotional use.
Slide 7: Factor Xa Inhibitor Bleeding – A Major and Growing Problem
IMS U.S. Factor Xa Units. Oct. 2017 – Oct. 2018. Truven Healthcare Analytics, a claims database with healthcare data for more than 43.6 million covered lives. Dec. 2017 Portola Market Research Studies: Aristotle, Averroes, Rocket, Einstein & Engage-AF Studies: Aristotle & Rocket Truven Factor Xa Inh
Slide 8: Increasing Need for the First FXa Antidote
Increasing Need for the First FXa Antidote CHMP Decision (end of Feb.) 2019 - 2021 2022 and Beyond Label Update: ANNEXA-4 data ANNEXA-4 Full Results Presentation and Publication (Feb. 7) Label Expansion Edoxaban/ Enoxaparin Label Expansion Urgent Surgery Generic Factor Xa Inhibitors 2023+ +60 - 100,
Slide 9: Andexxa – Addressing the Unmet Need
Andexxa – Addressing the Unmet Need 83% Excellent / Good Hemostatic Efficacy First and only FDA-approved antidote for patients treated with apixaban or rivaroxaban First-line recommendation in multiple guidelines Modified Factor Xa Decoy EFFECTIVE FAST SPECIFIC SUPPORTED >90% reduction of anti-Xa ac
Slide 10: Extensive Physician and Pharmacist Research Shows…
Extensive Physician and Pharmacist Research Shows… Andexxa Awareness (Unaided) Therapeutic Rating of Andexxa “This product is superior to what is out there on all the most important, relevant endpoints for these patients.” –Pharmacy Director For investor discussions only. Not for promotional use. 1.
Slide 11: Broad Commercial Launch Underway
Broad Commercial Launch Underway GEN2 Approved Andexxa shipping this morning! Initiating Full Commercial Effort 78 reps on the ground, onboarding of 40 additional reps underway Launched comprehensive print/digital campaigns 60 HCPs trained for speakers bureau (75 by end of Q1) Ensuring Reimbursement
Slide 12: Andexxa Demand is Strong and Growing
Andexxa Demand is Strong and Growing For investor discussions only. Not for promotional use. 40% 50% Two consecutive quarters of expectation-beating revenues $2.2 (Q2) $7.7 (Q3) 100 200 Increasing % of hospitals with reorders (Q3 YTD* Q4 YTD) Doubled the # of hospitals stocked (Q3 YTD Q4 YTD) ~100 ~
Slide 13: Launch Strategy in Europe (Ondexxya)
Launch Strategy in Europe (Ondexxya) For investor discussions only. Not for promotional use. Regulatory Timeline CHMP opinion expected in late Feb Potential EMA approval in Q2 Potential EU launch in 2H 2019 50% higher FXa use than U.S. Efficient sales and marketing Initial launch countries Germany,
Slide 14: CERDULATINIB
CERDULATINIB For investor discussions only. Not for promotional use.
Slide 15: Cerdulatinib: Urgent Need for New Treatment Options in PTCL and CTCL
2,000 relapsed/refractory Cerdulatinib: Urgent Need for New Treatment Options for Relapsed/Refractory Patients with PTCL and CTCL For investor discussions only. Not for promotional use. Significant unmet need for an oral agent that delivers higher response rates and a better safety profile PTCL CTCL
Slide 16: Phase 2a Response Summary in Target Populations
Phase 2a Response Summary in Target Populations For investor discussions only. Not for promotional use. PTCL CTCL Overall AITL (sub-type) N Evaluable 41 14 27 ORR 34% 57% 26% CR 27% 50% 7% Woman with MEITL, POD with EPOCH Baseline Day 26 Man with Refractory MF Baseline Day 140 End of Phase 2 meeting
Slide 17: BEVYXXA
BEVYXXA For investor discussions only. Not for promotional use.
Slide 18: Focused Commercial Strategy on Centers Of Excellence
Focused Commercial Strategy on Centers Of Excellence For investor discussions only. Not for promotional use. Focused effort on a small number of high potential accounts Simultaneously exploring potential partnership opportunities
Slide 19: Financial Discipline
Financial Discipline $380.9 in cash, cash equivalents and investments (9/30/18) Supports successful launch of Andexxa and continued development of cerdulatinib Strategic cost management resulted in: Financial resources to drive momentum into Q2 2020 Improved 2018 OpEx guidance to $355M - $365M (a re
Slide 20: Opportunity to impact millions of patient lives with Andexxa
For investor discussions only. Not for promotional use. Opportunity to impact millions of patient lives with Andexxa Progress and momentum in executing our plan We have the right team Portola in 2019…
Slide 21: Portola Pharmaceuticals
PORTOLA PHARMACEUTICALS NASDAQ: PTLA
Portola Pharmaceuticals — Corporate Update (January 2019) on 6ix